Clinical Trial

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-23.
Trial Details
NCT Number NCT06571461
Lead Sponsor CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions Pancreatic Cancer
Enrollment 408 participants
Start Date 2024-09
Primary Completion 2028-01 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2024-08-27